Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A; ACCENT Group. Sargent DJ, et al. Among authors: francini g. J Clin Oncol. 2007 Oct 10;25(29):4569-74. doi: 10.1200/JCO.2006.10.4323. Epub 2007 Sep 17. J Clin Oncol. 2007. PMID: 17876008
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. Gill S, et al. Among authors: francini g. J Clin Oncol. 2004 May 15;22(10):1797-806. doi: 10.1200/JCO.2004.09.059. Epub 2004 Apr 5. J Clin Oncol. 2004. PMID: 15067028
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Sargent DJ, et al. Among authors: francini g. J Clin Oncol. 2005 Dec 1;23(34):8664-70. doi: 10.1200/JCO.2005.01.6071. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260700
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.
Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Sargent D, et al. Among authors: francini g. J Clin Oncol. 2009 Feb 20;27(6):872-7. doi: 10.1200/JCO.2008.19.5362. Epub 2009 Jan 5. J Clin Oncol. 2009. PMID: 19124803 Free PMC article.
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.
Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ. Cheung WY, et al. Among authors: francini g. J Clin Oncol. 2016 Apr 10;34(11):1182-9. doi: 10.1200/JCO.2015.65.1158. Epub 2016 Feb 8. J Clin Oncol. 2016. PMID: 26858337 Free PMC article.
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A; Adjuvant Colon Cancer End-points (ACCENT) Group. Sargent D, et al. Eur J Cancer. 2011 May;47(7):990-6. doi: 10.1016/j.ejca.2010.12.015. Epub 2011 Jan 21. Eur J Cancer. 2011. PMID: 21257306 Free PMC article.
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G. Correale P, et al. Among authors: francini g. J Clin Oncol. 2005 Dec 10;23(35):8950-8. doi: 10.1200/JCO.2005.12.147. Epub 2005 Aug 1. J Clin Oncol. 2005. PMID: 16061910 Clinical Trial.
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma.
Petrioli R, Coratti A, Correale P, D'Aniello C, Grimaldi L, Tanzini G, Civitelli S, Marsili S, Messinese S, Marzocca G, Pirtoli L, Francini G. Petrioli R, et al. Among authors: francini g. Am J Clin Oncol. 2002 Oct;25(5):468-73. doi: 10.1097/00000421-200210000-00009. Am J Clin Oncol. 2002. PMID: 12393986 Clinical Trial.
142 results